29.11.2017 • NewsElaine BurridgeChinaInnovation

AstraZeneca Forms Chinese JV

© AstraZeneca
© AstraZeneca

AstraZeneca has formed a joint venture with China’s Future Industry Investment Fund (FIIF) to accelerate local development of innovative medicines for patients in China and around the world.

Both partners own an equal share in the standalone company, called Dizal Pharmaceutical. Xiaolin Zhang, previously head of AstraZeneca’s Innovation Center China (ICC), has been appointed as Dizal’s CEO.

Dizal, which incorporates all scientific and technical capabilities of the ICC, holds exclusive rights to three potential medicines from the Anglo-Swedish group’s pipeline that are currently in preclinical development. The jv is also expected to initiate its own novel clinical programs.

FIFF, which is managed by SDIC Fund, a private equity company focused on investment in China, will contribute funds and expertise in establishing strategic partnerships in the country.

SDIC Fund chairman, Guohua Gao, said the synergy created by combining AstraZeneca’s scientific talent and assets with FIIF’s China expertise and funding will help further promote innovation in medical science.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.